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Epilepsy is the most common serious neurological disorder worldwide. Approximately 70% of patients 
with epilepsy have their seizures controlled by clinical and pharmacological treatment. This research 
evaluated the possible influence of interchangeability among therapeutic equivalents of LTG on the 
clinical condition and quality of life of refractory epileptic patients. The study was divided into three 
periods of 42 days, and an equivalent therapeutic LTG randomly dispensed for each period (two similars 
- formulations A and B, and the reference product - formulation C). The mean dose of LTG was 5.5 
mg/kg/day. The presence of side effects tends to have a greater deleterious effect on quality of life of 
refractory epileptics compared to variations in number of seizures or changes in plasma concentrations. 
The results showed that independently of the drug prescribed, interchangeability among therapeutic 
equivalents can negatively impact epilepsy control.
Uniterms: Epilepsy/treatment. Lamotrigine/therapeutic equivalents. Drugs/interchangeability.
Epilepsia é o distúrbio neurológico grave mais comum no mundo todo. Aproximadamente 70% dos pacientes 
com epilepsia têm suas crises controladas com tratamento clínico e farmacológico. Esta pesquisa avaliou 
a possível interferência da intercambialidade entre equivalentes terapêuticos da lamotrigina na condição 
clínica e na qualidade de vida dos pacientes com epilepsia refratária. O estudo foi dividido em três períodos 
de 42 dias e em cada período foi dispensado um equivalente terapêutico, aleatoriamente (dois similares 
- formulação A e B e o medicamento de referência - formulação C). A dose média de lamotrigina foi de  
5,5 mg/kg/dia. A ocorrência de efeitos colaterais tende a ser mais decisiva para a redução da qualidade de 
vida em epilepsia refratária em relação às variações no número de crises ou alterações nas concentrações 
plasmáticas. Os resultados demonstram que, independentemente do medicamento prescrito, a 
intercambialidade entre equivalentes terapêuticos pode interferir no sucesso do controle da epilepsia.
Unitermos: Epilepsia/tratamento. Epilepsia/controle. Lamotrigina/equivalentes terapêuticos. 
Medicamentos/intercambialidade.
INTRODUCTION
Epilepsy is characterized by recurrent and unpro-
voked seizures constituting a transient sign and symptom 
of abnormal excessive electrical activity in the cerebral 
cortex (Fisher et al., 2005). The condition is the most 
common serious neurological illness worldwide, affect-
ing around 50 million people, 40 million of whom reside 
in developing countries (Burneo, Tellez-Zenteno, Wiebe, 
2005; Pellock, 2007). The incidence of epilepsy ranges 
from 11 to 131/100000 inhabitants per year with a global 
prevalence of 1.5 to 30/1000 inhabitants. The prevalence 
of epilepsy in Brazil is between 5.4/1000 and 18.6/1000 
(Marino Junior, Cukiert, Pinho, 1986; Borges et al., 2005; 
Li et al., 2007).
Although recent decades have seen advances in 
vagal stimulation and surgery for epilepsy (Betting et 
al., 2003), pharmacological treatment remains the first 
choice for controlling epilepsy (Löscher, 2002). Improved 
comprehension of epilepsy in the late twentieth century 
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led to the development of new antiepileptic drugs (AEDs) 
(Brodie, 2003), such as lamotrigine (LTG). However, 
30% of epileptic patients do not respond satisfactorily to 
pharmacological treatment and are considered refractory.
LTG was approved by the Food and Drug Admin-
istration in 1995. For this study, LTG was available in 
Brazil as Lamictal® (GlaxoSmithKline), considered the 
reference drug, Lamotrigine (Arrow), the generic drug 
and as Lamitor® (Torrent Brazil), Lamotrix® (Biolab 
Sanus), Neural® (Cristália) and Nortrigin® (Meizler), 
all considered similar drugs. However, to be deemed 
interchangeable pharmaceutical products need to be both 
pharmaceutically equivalent and bioequivalent (WHO, 
2006), whereas similar drugs in Brazil do not have to be 
tested for bioequivalence.
The Brazilian National Health System supplies epi-
leptic patients with LTG free of charge, but the prescrip-
tion of the drug is based on a Clinical Protocol created in 
2002 by the State Health Department (Brasil, 2002). The 
acquisition of LTG by Brazilian public health authorities 
is based in Federal Law 866 (07/21/1993), which allows 
acquisition by public tender, where the government invites 
rival bids for supply of pharmaceutical equivalents (Marin 
et al., 2003).
During the acquisition of LTG, the public health 
authorities do not distinguish among reference, generic or 
similar drugs. Therefore, manufacturers of similar drugs 
often win the public tender, because they generally prac-
tice lower prices in the market. In addition, some public 
tenders may occur during the year and this increases the 
possibility of switches in the therapeutic equivalent of 
the LTG.
The substitution among therapeutic equivalents 
has been discussed in the literature, because such shifts 
typically lead to observed changes in clinical efficacy 
and increases in medical appointments, hospitalizations 
and side effects (Krämer et al., 2007). This is particularly 
relevant among refractory epileptic patients, where the 
risk of recurrence of seizures can cause psychological 
and social damage, reducing quality of life (Makus, Mc-
Cormick, 2007).
Besides control of seizures and side effects, quality 
of life should also be considered during chronic treatment 
of refractory epilepsy, because this parameter is increas-
ingly important for management of the illness (Seidl, 
Zannon, 2004), allied with the development of instruments 
for measuring quality of life in epileptic patients (Wiebe 
et al., 2002). It is important to highlight that, in different 
cities throughout Brazil, a lack of adequate knowledge 
about the disease was noted rendering it a stigmatizing 
condition influencing patients’ activities of daily living 
and quality of life (Fernandes, Noronha, Sander, 2008; 
Vancini et al., 2010).
Therefore, the present study evaluated the possible 
impact on quality of life of refractory epileptic patients of 
interchangeability among therapeutic equivalents of LTG.
METHODS
The study was conducted at the Epilepsy Outpatient 
Clinic of the Ribeirão Preto Medical School University 
Hospital. The study was prospective and double blind, 
and previously approved by the Local Research Ethics 
Committee. Patients were included after meeting the fol-
lowing criteria: refractory epilepsy, at least three seizures 
in the last six months, age 18 to 65 years, in use of LTG in 
mono or polytherapy for at least two years, hematological 
and biochemical tests (renal and hepatic function) without 
clinically significant changes and agreement to the condi-
tions of the study.
The dosage of LTG and other AEDs used concomi-
tantly were maintained for all patients during the study 
period and the use of drugs and substances that could in-
terfere with the pharmacokinetics of LTG was not allowed, 
otherwise the patients were excluded from the study.
The study was divided into three periods of 42 days, 
spanning a total period of 126 days. For each period, an 
LTG therapeutic equivalent was randomly dispensed to 
patients, such that by the end of the study all patients had 
received two similar drugs (formulation A and B) and a 
reference drug (formulation C) of LTG; the drugs dispensed 
were drawn from the same lot. No generic formulation was 
included in this study, because generic formulation are usu-
ally not acquired by the Brazilian public health authorities 
since they tend to be more expensive than similar drugs.
The first 14 days of each of the three periods were 
not considered for the final results of number of seizures, 
plasma concentrations of LTG and side effects, because 
this interval was needed for reaching the steady state con-
centration in plasma, ensuring the results were not affected 
by the therapeutic equivalent of LTG tested previously. 
The blood collected was used to quantify the plasma con-
centration of LTG and for biochemical and hematological 
routine laboratory tests.
Study Procedures
The treatment was started and patients monitored 
through clinical appointments held on the following days: 
zero (baseline), at days 14, 42, 56, 84, 98 and 126 . At 
baseline, 42 and 84 days all patients received the formu-
lations of the LTG. The diary for recording seizures was 
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delivered at baseline and drugs selected were dispensed, 
with a sufficient number of tablets to last up until the next 
appointment.
The “Quality of Life in Epilepsy-31 Inventory” 
(QOLIE-31) is a specific instrument used to measure the 
quality of life of patients with Epilepsy and was assessed 
at baseline, and on days 42, 84 and 126. The QOLIE-31 
contains 31 questions investigating worry of these patients 
about their crisis, adverse effects, and cognitive aspects. 
The instrument is organized into seven domains, namely: 
Seizure Worry, Emotional Well-Being, Energy/Fatigue, 
Social Functioning, Cognitive Functioning, Medication 
Effects, Overall Quality of Life and an additional item as-
sessing overall health status. Each domain is scored from 
0 to 100 and the QOLIE-31 also has an overall score of 0 
to 100 (Silva et al., 2007).
On days 14, 42, 56, 84, 98 and 126, blood samples 
were collected for determination of plasma concentrations 
of LTG. At study end-point, patients returned to the routine 
of outpatient attendance. The determination of plasma 
concentrations of LTG was performed using HPLC-UV 
equipment and the reference interval was 2.5 – 15.0 mg/L.
The patients were monitored regarding adherence 
to treatment using the Morisky-Green test, whose score 
ranges from 0 to 4, with the latter value indicating the 
highest degree of adherence to pharmacological treatment.
The results found in this research were split into two 
parts (clinical data and quality of life) to aid discussion, 
since the purpose of this paper was to establish a relation-
ship between the interchangeability among therapeutic 
equivalents of LTG and quality of life of refractory epi-
leptic patients.
Statistical analysis
The results were assessed using mean ± standard 
deviation of the plasma concentration of LTG, number of 
seizures/week and domains of the QOLIE-31 on Student’s 
t-test for independent data. Student’s t test and ANOVA 
were performed by using software Instat® Graph, consid-
ering p values <0.05 statistically significant.
RESULTS AND DISCUSSION
Thirty patients attending the epilepsy center in treat-
ment for refractory epilepsy were invited to participate in 
the study, where only 13 accepted the invitation. Three 
subjects were excluded because they started smoking, had 
a new diagnosis of pseudo-crisis or required adjustment 
of the dose of other drugs to control seizures. Besides 
the three previously mentioned exclusions, an individual 
patient decided to leave the study after the first day. Thus, 
nine patients completed the study, maintaining the same 
dose of LTG throughout the 126 days of the study. This 
condition was necessary to allow comparison among the 
three formulations.
Seizures were recorded only in the 28 last days of 
each period for formulations A, B and C, disregarding the 
initial 14 days. Differences in plasma concentrations and 
number of seizures were not statistically significant for the 
small number of patients due to the difficulty recruiting 
according to the protocol. The adherence of patients to 
pharmacological treatment with LTG was assessed by the 
Morisky-Green test, and average score obtained was 3.7, 
4.0 and 3.7 for the formulations A, B and C, respectively. 
Thus, the values also showed no significant difference 
among the three formulations.
Patient 7 presented with a skin rash while using for-
mulation C and physicians provided early prescription of 
the another formulation of LTG before the 42 day period. 
In addition, patients 1, 6 and 9 showed mild side effects 
(drowsiness, dizziness and memory problems) while using 
formulation C, however due to the severity and duration 
of the side effects, the treatment with the formulation C 
was not discontinued by the physician. Also, two patients 
showed an increase in the number of seizures during the 
use of formulation B, needing to be switched over to an-
other formulation of LTG in this study.
Formulation A of LTG showed better results in the 
quality of life of epileptic patients than formulations B 
and C (Tables I, II, and III). Moreover, formulation A of 
LTG promoted significant improvement in the domains 
sociability and emotional aspects of the QOLIE-31, this 
result being due to a small number of seizures and no oc-
currence of side effects. 
Formulation B (Table II) promoted improvement in 
the global quality of life of patients and in a great number 
of domains, except vitality, but none of these results was 
significant. Formulation C (Table III) led to a decrease 
in the global quality of life of patients, but showed an in-
crease in the domain sociability, albeit without statistical 
difference. Table IV shows the mean of each formulation 
across the seven domains of the QOLIE-31.
Interchangeability among therapeutic equivalents 
during pharmacological treatment in epileptic patients has 
resulted in several publications, where authors describe 
that during the interchangeability of therapeutic equiva-
lents, the safety, efficacy and quality of the AEDs may suf-
fer variations. This difference may be relevant in epilepsy, 
because a small variation can decrease seizure control or 
promote side effects due to the narrow therapeutic range 
of most AEDs (Krämer et al., 2007).
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TABLE I - Results (initial versus final) on the QOLIE-31 (total and domains) for formulation A
Patient
Overall 
score
Social 
functioning
Medication 
effects
Cognitive 
functioning 
Energy-
fatigue
Emotional 
well-being 
Seizure 
worry 
Overall 
QOL
Initial Final** Initial Final* Initial Finalns Initial Finalns Initial Finalns Initial Final* Initial Finalns Initial Finalns
1 48.36 58.12 55 85 33.33 50.00 63.05 58.88 50 70 60 72 13 23 77.50 82.50
2 44.12 47.99 35 50 83.33 66.67 50.83 51.12 60 65 56 56 60 45 55.00 67.50
3 36.93 51.91 5 22 8.33 100 93.33 83.33 20 70 32 76 20 35 42.50 67.50
4 62.38 66.63 65 60 100 100 73.62 76.95 60 85 60 80 95 100 72.50 77.50
5 76.48 80.95 80 100 100 100 100 100 100 100 60 80 96 100 65.00 62.50
6 48.88 69.54 46 65 100 100 47.22 86.67 90 100 64 96 47 65 42.50 77.50
7 - 69.23 - 70 - 100 - 67.22 - 95 - 100 - 81 - 100
8 69.87 50.31 80 65 100 91.67 80.28 52.78 85 50 96 56 100 64 62.50 55.00
9 38.37 50.47 47 75 16.67 50.00 30.00 48.88 70 75 64 72 18 28 65.00 55.00
Mean 53 58 52 66 68 84 67 70 67 79 62 76 56 60 60 72
Legend: * statistically significant difference (p<0.05); ** statistically significant difference (p<0.01);) ns: no statistically significant difference (p>0.05).
TABLE II - Results (initial versus final) on QOLIE-31 (total and domains) for formulation B
Patient
Overall score
Social 
functioning
Medication 
effects
Cognitive 
functioning 
Energy-
fatigue
Emotional 
well-being 
Seizure 
worry 
Overall 
QOL
Initial Finalns Initial Finalns Initial Finalns Initial Finalns Initial Finalns Initial Finalns Initial Finalns Initial Finalns
1 58.12 - 85 - 50.00 - 58.88 - 70 - 72 - 23 - 82.50 -
2 47.99 44.38 50 55 66.67 83.33 51.12 50.55 65 55 56 56 45 28 67.50 50.00
3 51.91 57.62 22 45 100 75.00 83.33 96.67 70 60 76 72 35 13 67.50 75.00
4 59.60 61.44 48 55 0 83.33 95.83 82.78 65 60 56 76 100 95 50.00 65.00
5 80.95 68.92 100 68 100 100 100 100 100 75 80 88 100 74 62.50 60.00
6 65.27 66.97 53 80 83.33 100 93.33 63.62 80 95 76 76 100 100 55.00 67.50
7 63.04 80.68 100 80 83.33 100 59.72 96.67 80 100 48 100 15 91 85.00 100
8 43.54 63.05 55 75 83.33 91.67 30.83 57.78 75 90 72 80 51 85 50.00 72.50
9 50.47 49.19 75 67 50.00 33.33 48.88 54.17 75 55 72 60 28 23 55.00 72.50
Mean 55 62 65 66 69 83 69 75 76 74 68 76 55 64 64 70
Legend: ns: no statistically significant difference (p>0.05).
TABLE III - Results (initial versus final) on QOLIE-31 (total and domains) for formulation C
Patient
Overall score
Social 
functioning
Medication 
effects
Cognitive 
functioning 
Energy-
fatigue
Emotional 
well-being 
Seizure 
worry 
Overall 
QOL
Init Finalns Init Finalns Init Finalns Init Finalns Init Finalns Init Finalns Init Finalns Init Finns
1 - 52.93 - 50 - 41.67 - 69.72 - 70 - 68 - 48 - 65.00
2 44.38 45.89 55 50 83.33 75.00 50.55 53.62 55 60 56 52 28 46 50.00 50.00
3 57.62 76.19 45 95 75.00 75.00 96.67 93.33 60 90 72 84 13 56 75.00 87.50
4 61.44 62.38 55 65 83.33 100 82.78 73.62 60 60 76 60 95 95 65.00 72.50
5 68.92 77.40 68 100 100 100 100 100 75 85 88 80 74 100 60.00 50.00
6 66.97 46.88 80 46 100 100 63.62 47.22 95 90 76 64 100 47 67.50 42.50
7 80.68 - 80 - 100 - 96.67 - 100 - 100 - 91 - 100 -
8 63.05 69.87 75 80 91.67 100 57.78 80.28 90 85 80 96 85 100 72.50 62.50
9 49.19 37.19 67 51 33.33 25.00 54.17 37.50 55 5 60 60 23 5 72.50 50.00
Mean 62 59 66 67 83 77 72 69 74 68 76 71 64 62 70 61
Legend: ns: no statistically significant difference (p>0.05).
Interchangeability among therapeutic equivalents of lamotrigine: evaluation of quality of life 99
The Brazilian Agency of Sanitary Vigilance (AN-
VISA) allows and regulates the commercialization of 
reference, generic and similar drugs by Resolution RDC 
17 (03/03/2007). The similar drugs must contain the 
same active moiety, concentration, form, route of admin-
istration, dosage and therapeutic indication, and must 
be equivalent to the product registered at the ANVISA. 
However, the similar drugs may differ in the characteristics 
related to size and shape of the product, besides packaging 
and excipients.
 Law 9787/99 provides for the creation of generic 
drugs and Resolution 391 (09/08/1999) of the ANVISA 
allows the interchangeability among generic and reference 
drugs. This same law stipulates that similar drugs must be 
approved on a bioequivalence test, but these similar drugs 
are marketed without passing the bioequivalence test be-
cause the regulatory legislation that requires this has been 
approved, but does not yet take effect. However, during 
the public tender process, the Brazilian health authorities 
allow the participation of reference, generic and similar 
drugs with the latter usually winning the public tender 
because of their lower price.
In addition, during the year some public tenders are 
executed by Brazilian health authorities and this fact sup-
ports interchangeability among therapeutic equivalents 
of the LTG. However, this change during the pharmaco-
logical treatment often occurs in parallel to modifications 
in size or color of the drug and/or packaging, which can 
reduce compliance, because generally the patients have 
doubts whether this “new drug” is the same drug as that 
received before. This problem is most common in patients 
with cognitive problems, often found among epileptics. 
Moreover, this change frequently raises anxiety, increasing 
reports of side effects (Krämer et al., 2007).
A study has shown, according to clinical experi-
ence of the neurologists involved, that 68% of cases of 
interchangeability among reference and generic AEDs 
result in recurrence of seizures in previously-controlled 
patients (Wilner, 2004). The substitution of Lamictal® 
for a generic drug in epileptic patients, evaluated by 71 
pharmacists and 130 physicians, showed an increase 
in seizures (Makus, McCormick, 2007). Another study 
observed that the interchangeability did not reduce cost, 
because it generally results in an increase and/or addition 
of another drug to treatment and also increases medical 
utilization (Labiner et al., 2010).
Thus, the prescription of generic, similar or refer-
ence drug has been suggested only at the beginning of the 
epilepsy pharmacological treatment, where the physician 
is charged with choosing the most appropriate pharma-
ceutical equivalent (Krämer et al., 2007; Bialer, 2007). 
For patients who are free of seizures and side effects, 
interchangeability among AEDs is not recommended 
(Bialer, 2007).
In the United States of America, 95% of epilep-
tics agree that the interchangeability among therapeutic 
equivalent of AEDs promote increased seizures and/or side 
effects (Macauley et al., 2009), where it is commonplace 
for patients to return to the formulation used previously 
(Andermann et al., 2007).
Table V shows that the interchangeability among 
therapeutic equivalents of LTG did not promote signifi-
cant alterations in mean plasma concentrations of LTG 
or in number of seizures, where only patient 6 showed 
no change in seizures during the study. Moreover, higher 
mean plasma concentrations of LTG were found for for-
mulation B compared to other formulations, where this 
coincided with an increase in seizures/week. These results 
on the impact of interchangeability among therapeutics 
equivalents on plasma concentration of LTG and on the 
number of seizures/week (clinical data) were discussed in 
another study by the researchers (Girolineto et al., 2010).
Seizure control is important in refractory epilepsy, 
but increasing the dose of AEDs to achieve this goal, usu-
TABLE IV - Mean scores on QOLIE-31 (total and domains)
Therapeutic Equivalent Initial F A ns F B ns F C ns
Overall score 56.190 (±19.535) 60.572 (±11.479) 61.531 (±11.433) 58.466 (±14.985)
Social functioning 53.111 (±26.540) 65.778 (±21.919) 65.625 (±12.872) 67.125 (±21.781)
Medication Effects 54.628 (±39.332) 83.333 (±22.204) 83.291 (±22.397) 77.125 (±14.985)
Cognitive functioning 68.543 (±28.042) 69.540 (±18.042) 75.278 (±20.984) 69.409 (±22.054)
Energy-Fatigue 66.667 (±22.500) 78.889 (±17.280) 73.750 (±18.851) 74.375 (±14.745)
Emotional well-being 58.222 (±12.979) 76.444 (±15.158) 76.000 (±14.182) 70.500 (±14.803)
Seizure worry 52.556 (±38.204) 58.333 (±31.977) 63.625 (±36.063) 62.125 (±33.677)
Overall QOL 60.556 (±13.851) 71.667 (±14.416) 70.313 (±14.481) 60.625 (±14.01)
Legend: ns: no statistically significant difference (p>0.05).
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ally results in reduced of quality of life due to side effects 
(Perucca, 2000). Therefore, this study evaluated the impact 
of interchangeability among therapeutic equivalents of 
LTG on quality of life of refractory epilepsy patients based 
on the QOLIE-31. Refractory epilepsy severely impacts 
quality of life of patients due to the psychosocial disorders 
caused by the recurrence of seizures and the stigma and 
discrimination that increases during the evolution of the 
illness (Perucca, 2000).
Formulation A of LTG led to higher scores on the 
QOLIE-31 across the seven domains (Table I), while 
formulation B showed increase in six domains (Table II). 
The reduction observed in vitality caused by formulation 
B, although not significant, may be related to the increase 
in mean plasma concentration of LTG which can promote 
the occurrence of side effects (nausea, headache, depres-
sion, irritability and skin rash) (Mackay et al., 1997). 
Formulation C of LTG showed improvement only on the 
sociability domain of the QOLIE-31, reducing the final 
score of quality of life, but the alterations were not con-
sidered statistically significant (Table III).
These results demonstrate that formulation A re-
ceived the best rating with regard to quality of life, prob-
ably because this therapeutic equivalent showed better 
control over seizures and no side effects during the study. 
Table IV shows that the results obtained for the formula-
tions A, B and C on the QOLIE-31 all showed improve-
ment compared to baseline values.
However, evaluating the results for formulations B 
and C, reveals that the presence of side effects tends to 
carry greater weight in terms of the quality of life rating of 
refractory epileptic patients than number of seizures, be-
cause although formulation C reduced number of seizures 
compared to formulation B, the results showed that due to 
its side effects (although mild and transient), formulation 
C was associated with lower scores on the QOLIE-31.
Generally, epileptic teenagers have more social 
and cultural problems compared to epileptic adults, and 
this tends to more greatly reduce the quality of life these 
patients (Ding et al., 2008). Elsharkawy et al. (2009) dem-
onstrated that the duration of seizures and presence of side 
effects caused by AEDs have a greater negative impact 
on quality of life during the pharmacological treatment 
of epilepsy. The same authors observed that psychosocial 
factors, such employment, social independence and psy-
chiatric complications also adversely affect quality of life 
(Elsharkawy et al., 2009).
Phabphal et al. (2009) found that the frequency of 
seizures, depression and anxiety were responsible for 
decreases in quality of life of refractory epileptic patients. 
However, other factors evaluated (age, gender, occupa-
tion, marital status and medications) did not influence the 
results on the QOLIE-31. Piperidou et al. (2008) evaluated 
223 patients with mean age of 35.2 years and 13 years 
of epilepsy, and found that reduced quality of life was 
related to high seizure frequency and polytherapy, espe-
cially when patients used benzodiazepines associated with 
AEDs. Another study in Turkey also demonstrated that 
epileptic patients in polytherapy had lower quality of life 
compared to monotherapy patients (Giray et al., 2009).
One limitation of this study is the number of sub-
jects (n=9) included, involving a small sample precluding 
generalizations.
The authors can conclude that interchangeability 
TABLE V - Gender, age, dose, plasma concentration and seizure/week for formulations A, B and C of lamotrigine
Patient Gender Age
Dose (mg/
kg/day)
[plasma]LTG seizure / week
F Ans F Bns F Cns
14th day 42nd dayns 14th day 42nd dayns 14th day 42nd dayns F Ans F Bns F Cns
1 F 19 6.51 4.60 6.70 8.00 - 4.70 5.53 0.75 - 0.50
2 M 51 7.16 2.40 1.80 1.77 3.00 1.50 2.40 2.50 4.25 5.25
3 F 22 6.24 6.62 13.92 7.80 5.55 5.10 - 0.50 7.89 0
4 F 56 5.99 2.40 3.00 3.70 3.02 2.30 3.38 1.00 4.50 3.25
5 F 56 3.15 3.36 2.16 - - 3.70 6.20 0 4.00 0.25
6 F 58 5.62 1.64 - 2.70 3.80 12.90 2.20 0 0 0
7 M 28 5.00 10.90 9.80 12.60 16.90 5.70 - 1.50 0.25 -
8 M 31 6.46 4.10 1.74 - 2.40 1.60 3.80 0.75 0.25 0.75
9 M 43 3.52 4.85 4.60 - 8.50 5.00 4.30 0.25 1.50 1.50
Mean
40.44 
(±15.63)
5.52 
(±1.38)
4.54 
(±2.83)
5.47 
(±4.42)
6.10 
(±4.12)
6.17 
(±5.18)
4.72 
(±3.45)
3.97 
(±1.50)
0.81 
(±0.80)
2.83 
(±2.80)
1.44 
(±1.88)
Legend: ns: no statistically significant difference (p>0.05); F: formulation
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hampers control of refractory epilepsy due to the likeli-
hood of increasing seizures, presence of side effects and 
changes in plasma concentrations of LTG. Consequently, it 
proves difficult to maintain high scores on the QOLIE-31 
and reduction in quality of life can result.
Despite these results and the problem of similar 
drugs, the authors emphasize that the free supply of LTG 
is laudable, because it facilitates access of low income 
patients to high-cost drugs and allows physician greater 
choice for pharmacological treatment. Nevertheless, 
Brazilian health authorities should review the situation of 
similar drugs and find mechanisms to avoid frequent re-
placement of the therapeutic equivalent during treatment, 
because results show that independent of reference, gener-
ic or similar drugs, interchangeability among therapeutic 
equivalents tends to increase the likelihood of failure in the 
pharmacological treatment of refractory epilepsy.
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